Drug intelligence / Profile preview

CEQ508

Development stage: Unknown
Lead developer: Adhera Therapeutics
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**CEQ508** is an investigational orally administered RNAi therapeutic utilizing Cequent's transkingdom RNAi (tkRNAi) platform. It consists of engineered attenuated bacteria that deliver short-hairpin RNA (shRNA) specifically to dysplastic intestinal tissue, silencing **beta-catenin** (CTNNB1) mRNA to reduce protein levels in epithelial cells. Developed initially by Cequent Pharmaceuticals and Marina Biotech for **Familial Adenomatous Polyposis (FAP)**, a condition with dysregulated beta-catenin leading to colonic polyps and colorectal cancer risk, it received FDA IND approval, Fast Track designation, and advanced to Phase 2 trials, though development appears stalled.[1][2][4][7][16]

Other names: CEQ 508CEQ508CEQ-508

Targets

CTNNB1 (Beta-catenin)

Beyond the preview

Go deeper on CEQ508.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEQ508.

Explore the full profile